Navigation Links
AspenBio Pharma to Present at the Roth Capital Partners New York Investor Conference
Date:8/29/2007

CASTLE ROCK, Colo., Aug. 29 /PRNewswire-FirstCall/ -- AspenBio Pharma, Inc. (Nasdaq: APPY), an emerging bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for animals and humans, reported today the company has been invited to present at the annual Roth Capital Partners New York Investor Conference to be held September 5 and 6, 2007. More than 1,200 institutional investors are expected to attend the conference, which will be held at the Westin New York at Times Square.

AspenBio's CEO Richard Donnelly is scheduled to present on Thursday, September 6, at 2:00 P.M. Eastern Time. A simultaneous Webcast will be available at: http://www.wsw.com/webcast/roth13/apnb.ob.

Mr. Donnelly will discuss progress of AspenBio key products, including a specialized assay that detects a marker in the blood associated with appendicitis. According to three studies conducted during the past 33 months, including an ongoing 400 patient study, the company's AppyScore(TM) blood test has been able to identify patients with appendicitis at a very high sensitivity level of 94% to 97%. This compares to significantly lower diagnostic success rates for expensive CT scans, which are generally considered the best diagnostic method currently available for appendicitis. With the AppyScore emergency room triage test and its sister product, AppyScreen(TM), designed for physician offices, AspenBio is targeting a significant need for more economical, accurate and faster assessment of the appendicitis condition.

Roth Capital Partners Stock Conferences are among the largest in the nation for micro and small-cap companies in the technology,
'/>"/>

SOURCE AspenBio Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
2. Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System
3. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
4. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
5. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
6. Germantown drug company hires pharma veteran James Davidson as COO
7. Deltanoid Pharmaceuticals begins phase II osteoporosis study
8. New angel capital centered on GenTel agreement with big pharma
9. The deconstruction of Big Pharma
10. Big pharma seeks Wisconsin biotech partnerships
11. Doing the pharmaceutical tango
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... 2015 Outside GC, the leading provider ... addition of Debbie Casey as a member of the ... space. , Debbie has spent over 20 ... Fresenius Medical Care North America in both legal and ... to work with Outside GC’s growing list of healthcare ...
(Date:2/27/2015)... Nova Scotia (PRWEB) February 27, 2015 ... been made aware of a fraudulent press release disseminated ... purporting to be from Immunovaccine. This press release states ... Gilead Science, Inc. The press release did not ... the information contained within the press release. Please ...
(Date:2/27/2015)... CAMBRIDGE, Mass. , Feb. 27, 2015 /PRNewswire-USNewswire/ ... Analysis of the NCATS rare-diseases portfolio " in ... of a new financing technique to reduce the ... new diseases and potentially unlock new levels of ... The product of a unique collaboration between ...
(Date:2/27/2015)... 2015 The fully automated supercritical ... can sequentially analyze up to 48 samples utilizing ... detection of targets by mass spectrometry. , ... the measurement requirements of a wide range of ... delivery and search for disease biomarkers, additives in ...
Breaking Biology Technology:Outside GC Expands Healthcare Team 2Immunovaccine Disclaims Hoax Press Release 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3
... NeoStem, Inc.,(NYSE Alternext US: NBS), which is pioneering the pre-disease ... medical need,today announced that it has completed an above market ... $1.25 per unit with each unit,consisting of one share of ... stock at $1.75 per share. , ...
... SAN FRANCISCO, Calif., Dec. 3 Portola,Pharmaceuticals, a ... in cardiovascular disease, inflammatory disease,and cancer, today announced ... novel,compounds that inhibit spleen tyrosine kinase (Syk) and ... presented at the annual meeting of the,American Society ...
... , , QUEBEC CITY, ... AEZS ; TSX: AEZ), a global biopharmaceutical company ... has completed the transaction under the previously announced purchase ... ("CHRP") relating to AEterna Zentaris, rights to royalties on ...
Cached Biology Technology:NeoStem Completes $500,000 Private Placement With Strategic Investor 2NeoStem Completes $500,000 Private Placement With Strategic Investor 3Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting 2Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting 3AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners 2AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners 3
(Date:1/22/2015)... Showcase, Hall E -   EyeLock Inc. , a market ... showcase its EyeLock ID technology integrated in a 3D printed ... Oak Ridge National Laboratory (ORNL) at the 2015 ... technology is being used to validate the driver and authorize ...
(Date:1/22/2015)... Jan. 16, 2015  A man-made form of insulin delivered ... mental capabilities in adults with mild cognitive impairment and ... by researchers at Wake Forest Baptist Medical Center. ... amnesic mild cognitive impairment (MCI) or mild to moderate ...
(Date:1/22/2015)... and POINT ROBERTS, Washington , ... source covering leading sectors including technology and tech stocks, releases ... marketplace featuring master pickpocket and security consultant Apollo Robbins ... stolen and talks about the Wocket™ biometric smart wallet, a ...
Breaking Biology News(10 mins):EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3
... a unique vulnerability that can be exploited to make ... Washington University School of Medicine in St. Louis report. ... that tumors have a built-in mechanism that protects them ... benefit of hyperthermia and radiation as a combined therapy. ...
... way to rejuvenate dead nerve endings and a device ... among this years nine winners at NJITs annual provosts ... I walk through this showcase is the sophisticated array ... undergraduate students, said NJIT Provost Priscilla P. Nelson. ...
... the US, many people believe that the recent proliferation of ... people aim to significantly reduce the amount of saturated fats ... healthier, and happier. However, many leading researchers in the medical ... In FAT: ITS NOT WHAT YOU THINK (Prometheus, $15.95), technical ...
Cached Biology News:Researchers find way to make tumor cells easier to destroy 2NJIT applauds students for studies on brain injury, glaucoma and more 2Fat: Its not what you think! 2
Mouse monoclonal [002-49] to C1s ( Abpromise for all tested applications). entrezGeneID: 716 SwissProtID: P09871...
Goat polyclonal to HSPC150 ( Abpromise for all tested applications). entrezGeneID: 29089...
Oct 2 Immunogen: Full length human protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Mouse monoclonal [3B6] to HSV1 + HSV2 ICP5 Major Capsid Protein ( Abpromise for all tested applications)....
Biology Products: